false 0001851484 0001851484 2024-09-09 2024-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) September 9, 2024

 

 

 

Citius Oncology, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41534   99-4362660

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

11 Commerce Drive, 1st Floor, Cranford, NJ   07016
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 967-6677

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CTOR   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Pending further discussions with Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories, Ltd. (collectively, “Dr. Reddy’s”), Dr. Reddy’s agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc. (the “Company”), which was triggered upon regulatory approval of LYMPHIRTM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s and Citius Pharmaceuticals, Inc. (the “Asset Purchase Agreement”).

 

Except as set forth above, all other terms, conditions and rights of the Asset Purchase Agreement remain in full force and effect, which description was incorporated by reference into Current Report on Form 8-K filed by the Company on August 16, 2024.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CITIUS ONCOLOGY, INC.
   
Date: September 13, 2024 /s/ Leonard Mazur
  Leonard Mazur
  Chairman and Chief Executive Officer

 

 

2

 

v3.24.2.u1
Cover
Sep. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 09, 2024
Entity File Number 001-41534
Entity Registrant Name Citius Oncology, Inc.
Entity Central Index Key 0001851484
Entity Tax Identification Number 99-4362660
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11 Commerce Drive
Entity Address, Address Line Two 1st Floor
Entity Address, City or Town Cranford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07016
City Area Code 908
Local Phone Number 967-6677
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CTOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
TenX Keane Acquisition (NASDAQ:TENKU)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more TenX Keane Acquisition Charts.
TenX Keane Acquisition (NASDAQ:TENKU)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more TenX Keane Acquisition Charts.